Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Why Natera (NTRA) Stock Is Up Today

NTRA Cover Image

What Happened?

Shares of genetic testing company Natera (NASDAQ: NTRA). jumped 3% in the afternoon session after the company announced its Signatera molecular residual disease test was selected for a Phase III clinical trial for muscle-invasive bladder cancer. 

The trial, known as ARCHER, is sponsored by NRG Oncology and will evaluate whether shorter radiation therapy courses can achieve outcomes comparable to the current standard of care. The large-scale study is expected to enroll patients from over 100 sites across the United States and Canada. Natera's Signatera test, which is designed to detect residual cancer and recurrence, will serve as a pre-specified secondary endpoint in the trial. This inclusion follows other positive developments, including recent results from a separate Phase III trial that demonstrated Signatera's ability to predict immunotherapy benefits in bladder cancer patients after surgery, reinforcing the test's clinical utility.

After the initial pop the shares cooled down to $167.77, up 2.9% from previous close.

Is now the time to buy Natera? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Natera’s shares are quite volatile and have had 16 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 20 days ago when the stock gained 11.6% on the news that it reported strong second-quarter 2025 financial results, including a significant revenue beat and raised full-year guidance. The company posted revenue of $546.6 million, up 32.2% year-over-year and surpassing Wall Street's estimates by a notable 14.7%. This growth was supported by a 12.7% increase in the number of tests processed. However, it was not all positive, as Natera's GAAP loss per share of $0.74 came in wider than analysts had expected. Despite the earnings miss, investors were encouraged by the company's upgraded forecast. Natera lifted its full-year revenue guidance to a midpoint of $2.06 billion, an $80 million increase from its previous projection, signaling confidence in its continued growth trajectory.

Natera is up 4.5% since the beginning of the year, and at $167.77 per share, it is trading close to its 52-week high of $177 from February 2025. Investors who bought $1,000 worth of Natera’s shares 5 years ago would now be looking at an investment worth $2,606.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.